1. BPC-157 is not an approved drug — and that decides everything downstream

BPC-157 has no FDA approval for any indication in humans. That single fact drives the regulatory analysis: an unapproved new drug cannot be lawfully marketed for the prevention, treatment, or mitigation of any condition, and any claim of that kind converts the product into an illegally marketed drug regardless of how the label is worded.

Everything else on this list — marketing limits, channel limits, payment acceptance — flows from that starting point rather than from anything specific to peptides as a chemistry class.

2. Its compounding status closed the most common lawful-looking channel

Many sellers assumed the compounding pharmacy channel was the safe route. FDA has since categorized BPC-157 among bulk drug substances that raise significant safety risks for use in compounding, which effectively removes the compounding pathway that other peptides can still use. If your model depends on 503A patient-specific compounding or 503B office stock, verify the current status of the specific substance before you build anything around it — the categorization, not your intent, controls.

3. "Research use only" does not make a consumer sale lawful

RUO is a genuine designation for material sold to laboratories and institutional researchers, not a disclaimer that can be attached to a consumer checkout. When the buyer is an individual, the site is optimized for consumer search, the packaging is dose-convenient, and the support channel answers questions about human use, regulators and acquirers both read the transaction for what it is.

• RUO buyers are institutions with research purposes, and the paperwork shows it.
• A consumer-priced single vial with a checkout cart is not an institutional sale.
• A disclaimer does not cure a product page written for a human end user.

4. Your marketing is the evidence file

The most common cause of enforcement action and account termination alike is claims. Healing, recovery, injury repair, gut health, performance, dosing guidance — each is a therapeutic or performance claim, and each is trivially discoverable by a regulator, a competitor, or an acquirer's monitoring vendor.

The safe posture is factual, non-promotional information for a lawful audience: what the substance is, who may lawfully purchase it, and what documentation is required. Nothing about outcomes.

• No testimonials, before/after imagery, or influencer discount codes.
• No dosing, administration, or stacking guidance on public pages.
• Audit blog posts, FAQs, meta descriptions, and affiliate pages, not just the storefront.

5. It is banned in sport, which shapes who is searching for it

BPC-157 appears on the World Anti-Doping Agency prohibited list as a non-approved substance. That matters commercially as well as legally: a meaningful share of the search demand around it comes from athletes, and content or ad targeting that speaks to that audience signals performance marketing to anyone reviewing the business.

6. Purity and sourcing claims create their own liability

Independent testing of grey-market peptide supply has repeatedly found products whose contents do not match the label. If you publish a purity figure or a certificate of analysis, you are making a factual claim you must be able to substantiate for the specific lot in the customer's hands — not for a reference sample from a supplier deck.

• Keep lot-level certificates of analysis tied to what actually shipped.
• Retain supplier qualification records and change history.
• Never republish a supplier's COA as if it were your own testing.

7. State law adds a second, stricter layer

Federal status is the floor, not the ceiling. States regulate who may possess, dispense, and ship drug products, and several have moved independently on peptide sales and telehealth-driven distribution. A model that is defensible in one state can be unlawful in the next, so the shipping matrix has to be enforced at checkout rather than described in terms and conditions.

8. Who the seller of record is matters more than what the contract says

If a licensed entity is the party lawfully distributing the product, that entity should be the merchant of record for the transaction. When a marketing or platform company collects the money for a drug it is not licensed to sell, the arrangement is read as unlicensed distribution no matter how the agreements are drafted — and the payment flow is the record that proves it.

9. Payment acceptance is where the model gets tested

Acquirers and sponsor banks underwrite the catalog, the claims on your live URLs, the buyer verification controls, and the traceability of what shipped. A BPC-157 storefront aimed at consumers fails that review on the first two items, which is why those merchants cycle through short-lived aggregator accounts and sudden freezes.

A lawful B2B or licensed-channel program is a different conversation, but only if the documentation exists before the application. Sending a free statement review is the fastest way to see how your current setup reads to an underwriter — no obligation, and it comes back within 24 hours.

• Expect the catalog, the site, and the buyer controls to be reviewed as one file.
• Undisclosed products or channels are the fastest route to a termination.
• Keep a second processor warm so one decision cannot stop the business.

10. Decide the model before you decide the marketing

The sellers who last do the sequence in this order: confirm a lawful pathway for the specific substance, fix the seller of record and the buyer verification, strip claims from every surface, build lot-level traceability and a recall procedure, then approach payments with that file in hand. Reversing the order — build a storefront, drive traffic, then look for a processor — is what produces the frozen-account stories that dominate this category.